To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Gastric Cancer

Northwestern Medicine
Best-selling author V. Gilbert Beers surprises doctors and proves “age is just a number.”
Debbie's Dream
After turning to Debbie’s Dream, one woman shares how receiving support from fellow caregivers of loved ones with stomach cancer led to her to call on home health nurses throughout her husband’s journey.
Katie Kosko
A nearly 10-year stomach cancer survivor works with Debbie’s Dream Foundation to raise disease awareness and raise money for a cure.
Meeri N. Kim, Ph.D.
Patients with gastrointestinal cancers should be aware of specific side effects that might arise — and ways to prevent or ease them.
Kristie L. Kahl
An oncology dietitian offered advice on how to improve appetite and eat healthy before, during and after treatment for gastrointestinal cancers.
Dave Latham
Cancer can indeed be a numbers game, but I am no way just a statistic — no one is. This journey has given me a newfound perspective on life and the amazing work that Stand Up To Cancer does.
Kristie L. Kahl
The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.
Arlene Weintraub
Emerging facts about the genetics that drive gastric cancer are leading to new treatments for the disease.
Wayne Kuznar
Overall survival in metastatic gas­tric or gastroesophageal junction cancer improved significantly in patients who received the oral combination chemo­therapy Lonsurf regardless of whether they’d had a gastrectomy.
Wayne Kuznar
Nearly half of patients with a particular type of cholangiocarcinoma responded to a combination of two targeted drugs — Tafinlar (dabrafenib) and Mekinist (trametinib), which together inhibit the growth-signaling proteins BRAF and MEK in patients with different types of rare cancers that carry the BRAF V600E gene mutation.

Sign In

Not a member? Sign up now!
Continue without login